{"id":4047,"date":"2024-11-04T00:45:03","date_gmt":"2024-11-04T00:45:03","guid":{"rendered":"http:\/\/entrogen.com\/web4\/?post_type=product&p=4047"},"modified":"2025-06-23T18:14:04","modified_gmt":"2025-06-23T18:14:04","slug":"ras-mutation-screening-panel","status":"publish","type":"product","link":"https:\/\/entrogen.com\/web4\/product\/ras-mutation-screening-panel\/","title":{"rendered":"RAS Mutation Screening Panel"},"content":{"rendered":"[et_pb_section fb_built=”1″ admin_label=”Section” _builder_version=”4.27.2″ _module_preset=”default” custom_padding=”6px||4px|||” collapsed=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_wc_breadcrumb admin_label=”Woo Breadcrumbs” _builder_version=”4.16″ global_colors_info=”{}”][\/et_pb_wc_breadcrumb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” _builder_version=”4.27.2″ _module_preset=”default” custom_padding=”0px||9px|||” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_wc_images _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”|||-98px||” custom_padding=”|||23px||” global_colors_info=”{}”][\/et_pb_wc_images][\/et_pb_column][et_pb_column type=”2_3″ specialty_columns=”2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner column_structure=”1_2,1_2″ _builder_version=”4.27.2″ _module_preset=”default” custom_padding=”|0px||||” global_colors_info=”{}”][et_pb_column_inner type=”1_2″ saved_specialty_column_type=”2_3″ _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_wc_title _builder_version=”4.27.2″ _module_preset=”default” header_font_size=”27px” custom_margin=”|-164px||||” global_colors_info=”{}”][\/et_pb_wc_title][\/et_pb_column_inner][et_pb_column_inner type=”1_2″ saved_specialty_column_type=”2_3″ _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_wc_description admin_label=”Woo Product Short Description” _builder_version=”4.27.4″ custom_margin=”-8px|||||” global_colors_info=”{}”][\/et_pb_wc_description][et_pb_wc_meta show_sku=”off” admin_label=”Woo Product Meta” _builder_version=”4.27.2″ global_colors_info=”{}”][\/et_pb_wc_meta][et_pb_button button_url=”https:\/\/entrogen.com\/web4\/product-information-request-form\/” button_text=”Request More Information” button_alignment=”left” admin_label=”Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”13px” button_text_color=”#FFFFFF” button_bg_color=”#476e8d” button_border_color=”RGBA(255,255,255,0)” background_layout=”dark” custom_margin=”30px|||||” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” width=”100%” custom_padding=”6px|||||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_tabs admin_label=”Tabs” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”24px|||||” custom_padding=”|30px|60px|||” global_colors_info=”{}”][et_pb_tab title=”Product Overview” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]\n

Mutations in the KRAS gene, commonly found in metastatic colorectal cancer (mCRC), lung adenocarcinoma, and thyroid cancer, can make tumors resistant to anti-EGFR treatments. Studies show that mutations in exons 2, 3, and 4 of the KRAS and NRAS genes reduce the effectiveness of these therapies, leading experts, including the American Society of Clinical Oncology (ASCO), to recommend genetic screening before treatment.<\/p>\n

The RAS mutation analysis real-time assay utilizes allele-specific PCR, ensuring accurate detection using fluorescent hydrolysis probes. The panel is a qualitiavive test that detects somatic mutations found in exons 2, 3, and 4 of KRAS and NRAS genes. Below is a list of mutations detected by this kit.<\/p>\n

The RAS Mutation Screening Panel identifies the presence of the mutations in a total of 8 reactions per sample. The test does not distinguish between mutations within each group.<\/p>\n

*A complementary add-on reaction that distinguishes KRAS G12C from other codon 12 mutations is available, upon request.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Gene<\/strong><\/td>\nMutation<\/strong><\/td>\nGroup<\/strong><\/td>\nPercent (%) Prevalance1<\/sup><\/strong>
Colorectal Carcinoma<\/strong><\/td>\n		Percent (%) Prevalance1<\/sup><\/strong>
Colorectal Adenocarcinoma<\/strong><\/td>\n<\/tr>\n
KRAS<\/td>\nG12A, G12D, G12R, G12V, G13D<\/td>\n1<\/td>\n33.59<\/td>\n31.41<\/td>\n<\/tr>\n
G12C*, G12S<\/td>\n2<\/td>\n5.71<\/td>\n4.89<\/td>\n<\/tr>\n
Q61H, Q61L, Q61R, A59E, A59G, A59T<\/td>\n3<\/td>\n3.17<\/td>\n2.75<\/td>\n<\/tr>\n
K117N, K117R, K117E<\/td>\n4<\/td>\n0.9<\/td>\n0.92<\/td>\n<\/tr>\n
A146T, A146P, A146V<\/td>\n5<\/td>\n2.74<\/td>\n3.24<\/td>\n<\/tr>\n
NRAS<\/td>\nG12D, G12C, G12S, G13R, G13V, K117R<\/td>\n6<\/td>\n1.28<\/td>\n1.27<\/td>\n<\/tr>\n
Q61H, Q61L, Q61K, Q61R<\/td>\n7<\/td>\n2.26<\/td>\n2.35<\/td>\n<\/tr>\n
A59D, A59T, A146T<\/td>\n8<\/td>\nNo Data<\/td>\nNo Data<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n


1<\/sup> My Cancer Genome; www.mycancergenome.org (Colorectal Carcinoma, Colorectal Adenocarcinoma)<\/p>\n[\/et_pb_tab][et_pb_tab title=”Workflow” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]\n

The RAS Mutation Screening Panel follows a simple and easy to use process. The RAS Mutation Screening Kit can be completed in 2 hours and follows a far less complicated process.<\/p>\n

EntroGen\u02bcs RAS mutation screening panel requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. This test includes reagents required for PCR amplification\/detection, as well as validated reaction controls.<\/p>\n

Columns and reagents for DNA isolation are not included.\u00a0Genomic DNA from FFPE tissues can be extracted using EntroGen pureNA\u00ae Genomic DNA Isolation Kit<\/a>.<\/p>\n

We suggest using the <\/span>Internal Quality Control Assay (cat. no. IQCA<\/span><\/span>–<\/span><\/a>RT50)<\/a> to determine the optimal amount of input DNA prior to runnin<\/span>g this<\/span> assay.<\/span><\/span><\/p>\n

\"\"\"\"<\/a> \u00a0\u00a0 \"\" \u00a0\u00a0\"\" \"\"<\/a><\/p>\n

Click above to see <\/a>how it works<\/a><\/h5>\n[\/et_pb_tab][et_pb_tab title=”Resources” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]\n

<\/a><\/p>\n\n\n\n\n
\"\"<\/a><\/td>\nCetuximab in Treatment of Metastatic Colorectal Cancer: Final Survival Analyses and Extended RAS Data from the NORDIC-VII Study.<\/strong> Guren, Thomsen, Kure, Sorbye, Glimelius, Pfeiffer, \u00d6sterlund, Sigurdsson, Lothe, Dalsgaard, Skovlund, Christoffersen, Tveit. Comparison of KRAS Mutation Tests in Colorectal Cancer Patients. Br J Cancer. 2017 May 9;116(10):1271-1278. Pubmed ID 28399112<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\nEntroGen PCR Analysis Software (EPAS). Streamline reporting with simple data interpretation<\/strong><\/a>
Easy-to-interpret reports provide results that can be exported for integration with laboratory information management systems (LIS\/LIMS)<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Click to download lot-specific quality control data for your product:<\/p>\n

Download<\/span><\/a><\/a><\/u><\/p>\n

 <\/p>\n[\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_wc_related_products include_categories=”44″ show_price=”off” show_rating=”off” show_sale_badge=”off” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_wc_related_products][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"

Cat Number: RAS-RT50<\/strong><\/p>\n

The RAS Mutation Screening Panel is a PCR-based assay that detects somatic mutations in exons 2, 3, and 4 of KRAS and NRAS genes, which are linked to cancer and resistance to anti-EGFR therapies.<\/p>\n

 <\/p>\n